“Latest Stem Cells News”

Scientists have developed a new tool that illuminates connections between stem cells and cancer.
Researchers have been successful in breaking apart human prostate tissue, extract the stem cells in the tissue, and alter those cells genetically so that they spur cancer.

Many tissues contain pools of stem cells that replenish the tissue when it’s damaged or when changes take place. For example, stem cells in the skin produce new cells to replace those irreparably damaged by the sun, and stem cells in the breast create milk-producing cells when a woman is pregnant.

A characteristic of these stem cells is that they self-renew. This means that in addition to making cells with a specific function, they also make many new stem cells.

Incoming search terms:

UW-Milwaukee researcher Andrew Cohen has successfully developed a software program that facilitates predicting the evolution of stem cells. The program essentially speeds up what has been a tedious process for researchers in the past.

The program was published last week in the journal Nature Methods. It applies algorithmic information theory to the growth and movement of stem cells tracked over time to show what type of cells (i.e. brain, skin, etc.) they will eventually develop into.

“People look at images and take measurements by hand,” Cohen explained. “It takes a long time, and using computers makes the process a lot less tedious.”

Stem cells all start out the same before they develop into the different cells of our bodies. Scientists do not know what triggers the stem cell’s future growth pattern into a particular type of cell, but researchers like Cohen are figuring out how to predict the cell’s future based on measurements and math.

Incoming search terms:

Cultured stem cells from eyes helped improve the sight of eight patients with Limbal Stem Cell Deficiency, a painful, blinding disease, British doctors said.

The patients’ own corneal cells were cultured and used to reduce corneal cloudiness from the disease, The North East England Stem Cell Institute, Newcastle, England, reported in a release Thursday.

Incoming search terms:

CINCINNATI—New research from the University of Cincinnati may help in the recovery of lost vision for patients with corneal scarring.

Winston Whei-Yang Kao, PhD, professor of ophthalmology, along with other researchers in UC’s ophthalmology department found that transplanting human umbilical mesenchymal stem cells into mouse models that lack the protein lumican restored the transparency of cloudy and thin corneas.

Mesenchymal stem cells are “multi-potent” stem cells that can differentiate into a variety of cell types.

These findings are being presented Dec. 8 in San Diego at the 49th Annual Meeting of the American Society of Cell Biology.

“Corneal transplantation is currently the only true cure for restoration of eyesight that may have been lost due to corneal scarring caused by infection, mechanical and chemical wounds and congenital defects of genetic mutations,” Kao says. “However, the number of donated corneas suitable for transplantation is decreasing as the number of individuals receiving refractive surgeries, like LASIK, increases.”

“Worldwide, there is a shortage of suitable corneas for transplantation, and at the present time, there is no effective alternative procedure besides corneal transplantation to treat corneal blindness,” he continues. “There is a large need to develop alternative treatment regimens, one of which may be the transplantation of mesenchymal stem cells.”

Researchers used mouse models that did not have the lumican gene, also known as lumican knock-out models. Lumican is a protein that controls the formation and maintenance of transparent corneas.

“Lumican knock-out models manifested thin and cloudy corneas,” he says. “Transplantation of the umbilical stem cells significantly improved transparency and increased corneal stromal thickness in these mice.”

In addition, Kao says, the umbilical mesenchymal stem cells survived in the mouse stroma (connective tissue) for more than three months with minimal or no rejection and became corneal cells, repairing lost functions caused by mutations.

“Our results suggest a potential treatment regimen for congenital and/or acquired corneal diseases,” he says, adding that the availability of human umbilical stem cells is almost unlimited. “These stem cells are easy to isolate and can be recovered quickly from storage when treating patients.

“These findings have the potential to create new and better treatments—and an improved quality of life—for patients with vision loss due to corneal injury.”

This study was funded by grants from the National Eye Institute, Research to Prevent Blindness and the Ohio Lions Eye Research Foundation.

from http://healthnews.uc.edu/news/?/9613/

Incoming search terms:

Adult stem cells tested for defects before being implanted in the injured spinal cords of mice helped the animals recover with no cancerous side effects, according to new research. In recent years, scientists found that some experimental stem cell therapies can cause cancerous tumors. Pre-screened cells could result in potentially life- saving treatments without such side effects.

These new findings were presented at Neuroscience 2009, the annual meeting of the Society for Neuroscience and the world’s largest source of emerging news about brain science and health. “We tried to identify induced pluripotent stem cells from adult tissue that would be safe when applied to cell therapy for central nervous system disorders,” said Masaya Nakamura, MD, PhD, at Keio University School of Medicine, a co-author of the study. “These results suggest that properly pre-evaluated cells may be a promising source for future transplantation therapy.”

Here, the authors investigated the possibility of making transplantation therapies safer and more efficient by examining different types of stem cells. They generated 36 induced pluripotent stem cell clones, which differed in their origins and other characteristics. They found that the cell’s origin was a crucial indicator of whether the cells would result in tumors.

Results showed that immature (undifferentiated) stem cells are more likely to form tumors than mature ones. The transplantation of “safe” cells into mice with spinal cord injuries resulted in the formation of new neurons, while “unsafe” cells sped recovery for a short period but ultimately formed tumors.

“This study confirms that before human clinical trials go forward involving treatment of central nervous system disorders with induced pluripotent stem cells, pre-evaluating each cell clone carefully is essential,” Nakamura said.

from http://www.sciencedaily.com/releases/2009/10/091022115618.htm

Incoming search terms:

A clampdown on unproven and potentially unsafe stem cell research is being called for by an expert group.
Bionet, a group of expert Chinese and European doctors, lawyers and bioethicists, says countries throughout the world must develop more effective regulation for this emerging science (…)

They had provided a wealth of anecdotal evidence about their concerns that stem cell research was being moved too rapidly into clinical practice without proper study.
He said: “The key is informed consent. Doctors should be able to tell the patient about the short-term and long-term prognosis and the things we don’t know about the risks.”

Bionet is recommending that the safety and efficiency of stem cell treatments is investigated through state-of-the-art clinical trials before they are offered to patients (…)

And there should be quality standards for stem cells used in clinical practice.
These should include the bacterial and viral contamination applied during the production of the stem cells.

China introduced new regulations in May calling for clinical trials before stem cell treatments were offered to patients.
Professor Qui Renzong, vice-president of the ethics committee at the Chinese Ministry of Health, said: “In China there are about 150 institutions now providing stem cell therapy for diabetes through to spinal injuries.” (…)

“When stem cell ‘treatments’ are based overseas, regulatory oversight and jurisdiction is particularly problematic.
We take this very seriously and strongly encourage anyone considering participating in overseas stem cell ‘research trials’ or buying internet treatments to talk to their doctor and follow health guidelines.”

from http://news.bbc.co.uk/2/hi/health/8234206.stm

Incoming search terms: